by Azra Raza
Fojo, T., et al. “Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity: The John Conley Lecture.” JAMA Otolaryngology–Head & Neck Surgery 140, no. 12 (2014): 1225–1236.
Marchetti, S., and J. H. M. Schellens. “The Impact of FDA and EMEA Guidelines on Drug Development in Relation to Phase 0 Trials.” British Journal of Cancer 97 (2007): 577–581. www.nature.com/articles/6603925.
Kummar, Shivaani. “Compressing Drug Development Timelines in Oncology Using Phase ‘0’ Trials.” Nature Reviews Cancer 7 (2007): 131–139. www.nature.com/articles/nrc2066.
Murgo, J. A., et al. “Designing Phase 0 Cancer Clinical Trials.” Clinical Cancer Research 14, no. 12 (2008).
Spector, Reynold. “The War on Cancer: A Progress Report for Skeptics.” Skeptical Inquirer, January/February 2010.
Hitchens, Christopher. “Topic of Cancer.” Vanity Fair, August 2010.
Adams, C. P., and V. V. Brantner. “Estimating the Cost of New Drug Development: Is It Really 802 Million Dollars?” Health Affairs (Millwood) 25, no. 2 (2006): 420–428.
CHAPTER 5: JC
“Donor Registry Data.” US Department of Health and Human Services. https://bloodcell.transplant.hrsa.gov/research/registry_donor_data/index.html.
Koutsavlis, Ioannis. “Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes.” Anemia, 2016. doi:10.1155/ 2016/8494738.
Black Bone Marrow.com. http://blackbonemarrow.com/.
Poynter, J. N., M. Richardson, M. Roesler, C. K. Blair, B. Hirsch, P. Nguyen, A. Cioc, J. R. Cerhan, and E. Warlick. “Chemical Exposures and Risk of Acute Myeloid Leukemia and Myelodysplastic Syndromes in a Population-Based Study.” International Journal of Cancer 140, no. 1 (2017): 23–33. doi:10.1002/ijc.30420.
Murphy, T., and K. W. L. Yee. “Cytarabine and Daunorubicin for the Treatment of Acute Myeloid Leukemia.” Expert Opinion on Pharmacotherapy 18, no. 16 (2017): 1765–1780. doi:10.1080/14656566.2017.1391216.
Steele, John. “The Man Who Would Tame Cancer: Patrick Soon-Shiong Is Opening a New Front in the War on the Deadly Disease.” Nautilus, January 28, 2016.
Raza, A., et al. “Apoptosis in Bone Marrow Biopsy Samples Involving Stromal and Hematopoietic Cells in 50 Patients with Myelodysplastic Syndromes.” Blood 86, no. 1 (1995): 268–276.
Raza, A., et al. “Novel Insights into the Biology of Myelodysplastic Syndromes: Excessive Apoptosis and the Role of Cytokines.” International Journal of Hematology 63, no. 4 (1996): 265–278.
Raza, A., et al. “Thalidomide Produces Transfusion Independence in Long Standing Refractory Anemias of Patients with Myelodysplastic Syndromes.” Blood 98, no. 4 (2001): 958–965.
Raza, A., and N. Galili. “The Genetic Basis of Phenotypic Heterogeneity in Myelodysplastic Syndromes.” Nature Reviews Cancer 12, no. 12 (2012): 849–859. doi:10.1038/nrc3321.
CHAPTER 6: ANDREW
Wen, P. Y., and S. Kesari. “Malignant Gliomas in Adults.” New England Journal of Medicine 359 (2008): 492–507.
Stewart, L. A. “Chemotherapy in Adult High-Grade Glioma: A Systematic Review and Meta-Analysis of Individual Patient Data from 12 Randomised Trials.” Lancet 359 (2002): 1011–1018.
Kübler-Ross, Elisabeth. On Death and Dying. New York: Scribner, 1997.
Izard, Jason, and D. Robert Siemens. “What’s in Your Toolkit? Guiding Our Patients Through Their Shared Decision-Making.” Canadian Urological Association Journal 12, no. 10 (2018): 294–295.
Hagedoorn, Mariët, Ulrika Kreicbergs, and Charlotte Appel. “Coping with Cancer: The Perspective of Patients’ Relatives.” Acta Oncologica 50, no. 2 (2011): 205–211.
Wohlfarth, Philipp, et al. “Chimeric Antigen Receptor T-Cell Therapy—A Hematological Success Story.” Memo 11, no. 2 (2018): 116–121. doi:10.1007/s12254-018-0409-x.
Titov, Aleksei, et al. “The Biological Basis and Clinical Symptoms of CAR-T Therapy-Associated Toxicities.” Cell Death & Disease 9 (2018): article 897.
Fried, Shalev, et al. “Early and Late Hematologic Toxicity Following CD19 CAR-T Cells.” Bone Marrow Transplantation, 2019. https://doi.org/10.1038/s41409-019-0487-3.
Brudno, Jennifer N., and James N. Kochenderfer. “Chimeric Antigen Receptor T-Cell Therapies for Lymphoma.” Nature Reviews Clinical Oncology 15 (2018): 31–46.
Mahadeo, K. M. “Management Guidelines for Paediatric Patients Receiving Chimeric Antigen Receptor T Cell Therapy.” Nature Reviews Clinical Oncology 16 (2019): 45–63.
Hoos, A. “Development of Immuno-Oncology Drugs—From CTLA4 to PD1 to the Next Generations.” Nature Reviews Drug Discovery 15, no. 4 (2016): 235–247.
Coulie, P. G., B. J. Van den Eynde, P. van der Bruggen, and T. Boon. “Tumour Antigens Recognized by T Lymphocytes: At the Core of Cancer Immunotherapy.” Nature Reviews Cancer 14, no. 2 (2014): 135–146.
Schmidt, Charles. “The Struggle to Do No Harm in Clinical Trials: What Lessons Are Being Learnt from Studies That Went Wrong?” Nature, December 20, 2017.
Maude, S. L., et al. “Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.” New England Journal of Medicine 378, no. 5 (2018): 439–448.
Editorial. “CAR T-Cell Therapy: Perceived Need Versus Actual Evidence.” Lancet Oncology 19, no. 10 (2018): 1259.
Osorio, Joana. “Cancer Immunotherapy Research Round-Up: Highlights from Clinical Trials.” Nature, December 20, 2017.
Barreyro, L., T. M. Chlon, and D. T. Starczynowski. “Chronic Immune Response Dysregulation in MDS Pathogenesis.” Blood 132, no. 15 (2018): 1553–1560.
Almasbak, Hilde, et al. “CAR T Cell Therapy: A Game Changer in Cancer Treatment.” Journal of Immunology Research, 2016. doi:10.1155/2016/5474602.
Sun, Shangjun, et al. “Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies.” Journal of Immunology Research, 2018. doi:10.1155/2018/2386187.
Doudna, Jennifer A., and Samuel H. Sternberg. A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution. Boston: Houghton Mifflin Harcourt, 2017.
Haapaniemi, Emma, Sandeep Botla, Jenna Persson, Bernhard Schmierer, and Jussi Taipale. “CRISPR–Cas9 Genome Editing Induces a p53-Mediated DNA Damage Response.” Nature Medicine, 2018. doi:10.1038/s41591-018-0049-z.
Shin, Ha Youn, et al. “CRISPR/Cas9 Targeting Events Cause Complex Deletions and Insertions at 17 Sites in the Mouse Genome.” Nature Communications 8 (2017): article 15464.
Kosicki, Michael, et al. “Repair of Double-Strand Breaks Induced by CRISPR–Cas9 Leads to Large Deletions and Complex Rearrangements.” Nature Biotechnology 36 (2018): 765–771.
CHAPTER 7: HARVEY
Weir, Hannah K., et al. “The Past, Present, and Future of Cancer Incidence in the United States: 1975 Through 2020.” Cancer 121, no. 11 (2015): 1827–1837. doi:10.1002/cncr.29258.
By the Numbers: NCI Budget Breakdown, FY 2018. doi:10.1158/2159-8290.CD-NB2019-002.
Aparicio, Samuel, and Carlos Caldas. “The Implications of Clonal Genome Evolution for Cancer Medicine.” New England Journal of Medicine 368 (2013): 842–851. doi:10.1056/NEJMra1204892.
Walter, M. J., et al. “Clonal Architecture of Secondary Acute Myeloid Leukemia.” New England Journal of Medicine 366 (2012): 1090–1098.
Ruiz, C., E. Lenkiewicz, L. Evers, et al. “Advancing a Clinically Relevant Perspective of the Clonal Nature of Cancer.” Proceedings of the National Academy of Sciences of the United States of America 108 (2011): 12054–12059.
Cohen, Jon. “‘It’s Sobering’: A Once-Exciting HIV Cure Strategy Fails Its Test in People.” Science, July 25, 2018. doi:10.1126/science.aau8963.
Crowley, E., et al. “Liquid Biopsy: Monitoring Cancer-Genetics in the Blood.” Nature Reviews Clinical Oncology 10 (2013): 472–484.
Bleyer, Archie, and H. Gilbert Welch. “Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence.” New England Journal of Medicine 367, no. 21 (2012):
1998–2005.
Miller, Anthony B., et al. “Twenty Five Year Follow-Up for Breast Cancer Incidence and Mortality of the Canadian National Breast Screening Study: Randomised Screening Trial.” British Medical Journal 348 (2014): 366.
Fagin, Dan. Toms River: A Story of Science and Salvation. Washington, DC: Island Press, 2014.
Ilic, D., M. Djulbegovic, J. H. Jung, et al. “Prostate Cancer Screening with Prostate-Specific Antigen (PSA) Test: A Systematic Review and Meta-Analysis.” BMJ 362 (2018): k3519.
Loud, Jennifer, and Jeanne Murphy. “Cancer Screening and Early Detection in the 21st Century.” Seminars in Oncology Nursing 33, no. 2 (2017): 121–128.
Adami, Hans-Olov, et al. “Towards an Understanding of Breast Cancer Etiology.” Seminars in Cancer Biology 8, no. 4 (1998): 255–262.
Esserman, Laura J. “Overdiagnosis and Overtreatment in Cancer: An Opportunity for Improvement.” JAMA 310, no. 8 (2013): 797.
Autier, P., and M. Boniol. “Effect of Screening Mammography on Breast Cancer Incidence.” New England Journal of Medicine 368 (2013): 677–679. https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.691.3537 &rep=rep1&type=pdf.
Das, Srustidhar, and Surinder K. Batra. “Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy.” Cancer Research, 2015. doi:10.1158/0008-5472.CAN-15-1050.
Leaf, Clifton. The Truth in Small Doses: Why We’re Losing the War on Cancer—And How to Win. New York: Simon & Schuster, 2013.
Adami, Hans-Olov, et al. “Time to Abandon Early Detection Cancer Screening.” European Journal of Clinical Investigation, December 19, 2018. https://onlinelibrary.wiley.com/doi/full/10.1111/eci.13062.
Kopans, D. B. “Breast Cancer Screening: Where Have We Been and Where Are We Going? A Personal Perspective Based on History, Data and Experience.” Clinical Imaging 48 (2018): vii–xi.
Malvezzi, M., et al. “European Cancer Mortality Predictions for the Year 2019 with Focus on Breast Cancer.” Annals of Oncology, March 19, 2019. https://doi.org/10.1093/annonc/mdz051.
Malvezzi, M., et al. “European Cancer Mortality Predictions for the Year 2018 with Focus on Colorectal Cancer.” Annals of Oncology 29, no. 4 (2018): 1016–1022.
Prasad, V. “Why Cancer Screening Has Never Been Shown to ‘Save Lives’—And What We Can Do About It.” BMJ 352 (2016). https://doi.org/10.1136/bmj.h6080.
Narod, S. A., et al. “Why Have Breast Cancer Mortality Rates Declined?” Journal of Cancer Policy 5 (2015): 8–17. https://doi.org/10.1016/j.jcpo.2015.03.002.
Colantonio, S., et al. “A Smart Mirror to Promote a Healthy Lifestyle.” Biosystems Engineering 138 (2015): 33–43.
Iverson, N. M., et al. “In Vivo Biosensing Via Tissue Localizable Near Infrared Fluorescent Single Walled Carbon Nanotubes.” Nature Nanotechnology 8 (2013): 873–880.
Gambhir, Sanjiv Sam. “Toward Achieving Precision Health.” Science Translational Medicine 10, no. 430 (2018): 3612. doi:10.1126/scitranslmed.aao3612.
Wong, D. “Saliva Liquid Biopsy for Cancer Detection.” Paper presented at the American Association for the Advancement of Science 2016 Annual Meeting, Washington, DC, February 11–15, 2016.
Johnson, J. “Intelligent Toilets, Smart Couches and the House of the Future,” Financial Post, June 6, 2012. http://business.financialpost.com/uncategorized/intelligent-toilets-smart-couches-and-the-house-of-the-future.
Wang, Lulu. “Microwave Sensors for Breast Cancer Detection.” Sensors 18, no. 2 (2018): 655. https://doi.org/10.3390/s18020655.
Hsu, Jeremy. “Can a New Smart Bra Really Detect Cancer?” Live Science, October 17, 2012.
Kahn, N., et al. “Dynamic Nanoparticle-Based Flexible Sensors: Diagnosis of Ovarian Carcinoma from Exhaled Breath.” Nano Letters 15, no. 10 (2015): 7023–7028.
Czernin, Johannes, and Sanjiv Sam Gambhir. “Discussions with Leaders: A Conversation Between Sam Gambhir and Johannes Czernin.” Journal of Nuclear Medicine 59, no. 12 (2018): 1783–1785. doi:10.2967/jnumed.118.221648.
Vermesh, Ophir, et al. “An Intravascular Magnetic Wire for the High-Throughput Retrieval of Circulating Tumour Cells In Vivo.” Nature Biomedical Engineering 2, no. 9 (2018): 696–705.
Ferrari, E., et al. “Urinary Proteomics Profiles Are Useful for Detection of Cancer Biomarkers and Changes Induced by Therapeutic Procedures.” Molecules 24, no. 4 (2019): 794. https://doi.org/10.3390/molecules24040794.
Colditz, Graham A., Kathleen Y. Wolin, and Sarah Gehlert. “Applying What We Know to Accelerate Cancer Prevention.” Science Translational Medicine, 4, no. 127 (2012): 127rv4.
Wan, J. C., et al. “Liquid Biopsies Come of Age: Towards Implementation of Circulating Tumour DNA.” Nature Reviews Cancer 17 (2017): 223–238.
Bianchi, D. W. “Circulating Fetal DNA: Its Origin and Diagnostic Potential—A Review.” Placenta 25, supplement (2004): S93–S101. https://doi.org/10.1016/j.placenta.2004.01.005.
Jahr, S., et al. “DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for Their Origin from Apoptotic and Necrotic Cells.” Cancer Research 61 (2001): 1659–1665.
Thierry, A. R., et al. “Clinical Validation of the Detection of KRAS and BRAF Mutations from Circulating Tumor DNA.” Nature Medicine 20 (2014): 430–435.
Ding, L., M. C. Wendl, J. F. McMichael, and B. J. Raphael. “Expanding the Computational Toolbox for Mining Cancer Genomes.” Nature Reviews Genetics 15, no. 8 (2014): 556–570.
Murtaza, M., et al. “Non-Invasive Analysis of Acquired Resistance to Cancer Therapy by Sequencing of Plasma DNA.” Nature 497 (2013): 108–112.
Siravegna, Giulia, et al. “Integrating Liquid Biopsies into the Management of Cancer.” Nature Reviews Clinical Oncology 14 (2017): 531–548.
Taylor, D. D., and C. Gercel-Taylor. “MicroRNA Signatures of Tumor-Derived Exosomes as Diagnostic Biomarkers of Ovarian Cancer.” Gynecologic Oncology 110 (2008): 13–21.
Yuan, Zixu. “Dynamic Plasma MicroRNAs Are Biomarkers for Prognosis and Early Detection of Recurrence in Colorectal Cancer.” British Journal of Cancer 117 (2017): 1202–1210.
Hinkson, I., IV, et al. “A Comprehensive Infrastructure for Big Data in Cancer Research: Accelerating Cancer Research and Precision Medicine.” Frontiers in Cell and Developmental Biology, September 21, 2017. https://doi.org/10.3389/fcell.2017.00083.
Philippidis, Alex. “Next-Gen Diagnostics: Thermo Fisher Scientific, University Hospital Basel Partner to Develop, Validate NGS Cancer Diagnostics.” Clinical OMICs 4, no. 3 (2017). https://doi.org/10.1089/clinomi.04.03.17.
BloodPac: Blood Profiling Atlas in Cancer. www.bloodpac.org.
Liu, M. C., et al. “Plasma Cell-Free DNA (cfDNA) Assays for Early Multi-Cancer Detection: The Circulating Cell-Free Genome Atlas (CCGA) Study.” Annals of Oncology 29, supplement 8 (2018): mdy269.048. https://doi.org/10.1093/annonc/mdy269.048.
Sallam, Reem M. “Proteomics in Cancer Biomarkers Discovery: Challenges and Applications.” Disease Markers, 2015. http://dx.doi.org/10.1155/2015/321370.
Taylor and Gercel-Taylor. “MicroRNA Signatures.”
Peng, Liyuan. “Tissue and Plasma Proteomics for Early Stage Cancer Detection.” Molecular Omics 14 (2018): 405–423. doi:10.1039/C8MO00126J.
Tajmul, M. D., et al. “Identification and Validation of Salivary Proteomic Signatures for Non-Invasive Detection of Ovarian Cancer.” International Journal of Biological Macromolecules 108 (2018): 503–514.
Simpson, R. J., S. S. Jensen, and J. W. Lim. “Proteomic Profiling of Exosomes: Current Perspectives.” Proteomics 8 (2008): 4083–4099.
Chen, Ziqing, et al. “Current Applications of Antibody Microarrays.” Clinical Proteomics 15, no. 7 (2018). https://doi.org/10.1186/s12014-018-9184-2.
Halvaei, S. “Exosomes in Cancer Liquid Biopsy: A Focus on Breast Cancer.” Nucleic Acid 10 (2018): 131–141.
Xu, Rong, et al. “Extracellular Vesicles in Cancer—Implications for Future Improvements in Cancer Care.” Nature Reviews Clinical Oncology 15, no. 10 (2018): 617–638.
Valentino, A., et al. “Exosomal MicroRNAs in Liquid Biopsies: Future Biomarkers for Prostate Cancer.” Clinical and Translational Oncology 19 (2017): 651–657.
Rajagopal, C., and K. B. Harikumar. “The Origin and Functions of Exosomes in Cancer.” Frontiers in Oncology, March 20, 2018. https://doi.org/10.3389/fonc.2018.00066.
Rani, S., et al. “Isolation of Exosomes for Subsequent mRNA, MicroRNA, and Protein Profiling.” Methods in Molecular Biology 784 (2011): 181–195.
Liu, F., U. Demirci, and S. S. Gambhir. Exosome-Total-Isolation-Chip (ExoTIC) Device for Isolation of Exosome-Based Biomarkers. US patent application 16/073,577, filed 2019.
Alix-Panabieres, C., and K. Pantel. “Circulating Tumor Cells: Liquid Biopsy of Cancer.” Clinical Chemistry 59 (2013): 110–118.
Green, B. J., et al. “Beyond the Capture of Circulating Tumor Cells: Next-Generation Devices and Materials.” Angewandte Chemie International Edition 55 (2016): 1252–1265. https://onlinelibrary.wiley.com/doi/full/10.1002/anie.201505100%4010.1002/%28ISSN%291521-3773.Microfluidics.
Vona, G., et al. “Isolation by Size of Epithelial Tumor Cells: A New Method for the Immunomorphological and Molecular Characterization of Circulating Tumor Cells.” American Journal of Pathology 156, no. 1 (2000): 57–63.
Paterlini-Brechot, Patrizia, and Naoual Linda Benali. “Circulating Tumor Cells (CTC) Detection: Clinical Impact and Future Directions.” Cancer Letters 253, no. 2 (2007): 180–204.
Hood, Leroy, and Stephen H. Friend. “Predictive, Personalized, Preventive, Participatory (P4) Cancer Medicine.” Nature Reviews Clinical Oncology 8 (2011): 184–187.
Cohen, J. D., et al. “Combined Circulating Tumor DNA and Protein Biomarker-Based Liquid Biopsy for the Earlier Detection of Pancreatic Cancers.” Proceedings of the National Academy of Sciences of the United States of America 114, no. 38 (2017): 10202–10207. https://doi.org/10.1073/pnas.1704961114.
Wang, Qing, et al. “Mutant Proteins as Cancer-Specific Biomarkers.” Proceedings of the National Academy of Sciences of the United States of America 108, no. 6 (2011): 2444–2449. https://doi.org/10.1073/pnas.1019203108.
